Boehringer Ingelheim Entered into a Research Agreement with VantAI to Identify Novel Protein Degraders
Shots:
- VantAI to receive an upfront & is eligible to receive additional preclinical, clinical & commercial milestones. Boehringer gets an exclusive commercial right to degraders that are developed for the initial target & will be responsible for the development & commercialization
- The collaboration will combine VantAI's geometric deep learning platform with BI’s deep early discovery experience to identify targeted protein degraders with enhanced properties for undruggable targets
- The collaboration focus on 1 degrader program combined with multiple E3 ligase platforms. VantAI's geometric deep learning platform provides the computationally streamlined design of new molecules optimized for each E3 platform
Ref: Globe Newswire | Image: Boehringer Ingelheim
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
